Cancer Research Cancer Genome no Abstract
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fujimoto, A.
Right arrow Articles by Hoon, D. S. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fujimoto, A.
Right arrow Articles by Hoon, D. S. B.
[Cancer Research 64, 4085-4088, June 15, 2004]
© 2004 American Association for Cancer Research

Advances in Brief

Allelic Imbalance on 12q22-23 in Serum Circulating DNA of Melanoma Patients Predicts Disease Outcome

Akihide Fujimoto1, Steven J. O’Day2, Bret Taback1, David Elashoff3 and Dave S. B. Hoon1

1 Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California; 2 Cancer Institute Medical Group, Santa Monica, California; and 3 Department of Biomathematics, University of California at Los Angeles School of Medicine, Los Angeles, California

Allelic imbalance (AI) encompassing the apoptotic protease-activating factor 1 (APAF-1) locus (12q22-23) is found frequently in metastatic melanoma. Circulating DNA with AI on 12q22-23 in serum was evaluated as a surrogate marker to predict biochemotherapy (BC) treatment response in melanoma patients. Sera were collected from 49 American Joint Committee on Cancer stage IV melanoma patients treated with BC. Serum AI of the 12q22-23 region was demonstrated to be present before and/or after BC. BC responders showed a significantly lower frequency of AI (5 of 24, 21%) compared with nonresponders (11 of 20, 55%; Fisher’s exact test, P < 0.029). Serum AI on 12q22-23 was associated with worse prognosis (log-rank test, P < 0.046). These findings indicate that serial serum genetic analysis of tumor-related AI on 12q22-23 may have clinical use in predicting tumor response to therapy.




This article has been cited by other articles:


Home page
 CarcinogenesisHome page
B. Zhivotovsky and S. Orrenius
Carcinogenesis and apoptosis: paradigms and paradoxes
Carcinogenesis, October 1, 2006; 27(10): 1939 - 1945.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Umetani, A. E. Giuliano, S. H. Hiramatsu, F. Amersi, T. Nakagawa, S. Martino, and D. S.B. Hoon
Prediction of Breast Tumor Progression by Integrity of Free Circulating DNA in Serum
J. Clin. Oncol., September 10, 2006; 24(26): 4270 - 4276.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Mori, S. R. Martinez, S. J. O'Day, D. L. Morton, N. Umetani, M. Kitago, A. Tanemura, S. L. Nguyen, A. N. Tran, H.-J. Wang, et al.
Estrogen Receptor-{alpha} Methylation Predicts Melanoma Progression.
Cancer Res., July 1, 2006; 66(13): 6692 - 6698.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Koyanagi, T. Mori, S. J. O'Day, S. R. Martinez, H.-J. Wang, and D. S.B. Hoon
Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients.
Cancer Res., June 15, 2006; 66(12): 6111 - 6117.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
N. Umetani, J. Kim, S. Hiramatsu, H. A. Reber, O. J. Hines, A. J. Bilchik, and D. S. B. Hoon
Increased Integrity of Free Circulating DNA in Sera of Patients with Colorectal or Periampullary Cancer: Direct Quantitative PCR for ALU Repeats.
Clin. Chem., June 1, 2006; 52(6): 1062 - 1069.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Bajetta, M. Del Vecchio, P. Nova, A. Fusi, A. Daponte, M. R. Sertoli, P. Queirolo, P. Taveggia, M. G. Bernengo, S. S. Legha, et al.
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-{alpha}2b in metastatic melanoma
Ann. Onc., April 1, 2006; 17(4): 571 - 577.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Mori, S. J. O'Day, N. Umetani, S. R. Martinez, M. Kitago, K. Koyanagi, C. Kuo, T.-L. Takeshima, R. Milford, H.-J. Wang, et al.
Predictive Utility of Circulating Methylated DNA in Serum of Melanoma Patients Receiving Biochemotherapy
J. Clin. Oncol., December 20, 2005; 23(36): 9351 - 9358.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Mori, J. Kim, T. Yamano, H. Takeuchi, S. Huang, N. Umetani, K. Koyanagi, and D. S.B. Hoon
Epigenetic Up-regulation of C-C Chemokine Receptor 7 and C-X-C Chemokine Receptor 4 Expression in Melanoma Cells
Cancer Res., March 1, 2005; 65(5): 1800 - 1807.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.